SCHEMBL4404733

SCHEMBL4404733

CC(=O)OCc1ccc(CN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.39
CYP3A4 P08684 1/20 0.36
MTNR1A P48039 2/20 0.35
MTNR1B P49286 2/20 0.35
ALDH1A1 P00352 2/20 0.34
SSTR4 P31391 1/20 0.33
MAPT P10636 2/20 0.33
RAB9A P51151 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.32
PKM P14618 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TSHR P16473 1/20 0.32
CA2 P00918 1/20 0.32
AKT1 P31749 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4396244 0.85 GRM2 (0.41) GRM2MTNR1AMTNR1BSSTR4HDAC3
SCHEMBL4406042 0.79 GRM2 (0.43) GRM2ALDH1A1SSTR4HDAC3HDAC1
SCHEMBL4655268 0.78 CYP3A4 (0.55) CYP3A4ALDH1A1MAPTRAB9ANPC1
SCHEMBL10229493 0.76 GRM2 (0.42) GRM2ALDH1A1SSTR4MAPTHDAC3
SCHEMBL13234266 0.73 GRM2 (0.41) GRM2ALDH1A1HDAC3HDAC1HDAC2
SCHEMBL4398498 0.72 RIPK1 (0.53) GRM2KMT2AAKT1
SCHEMBL19022360 0.72 MAPT (0.43) CYP3A4ALDH1A1MAPTRAB9ANPC1
SCHEMBL19153416 0.71 AKT1 (0.43) GRM2SSTR4HDAC3HDAC1HDAC2
SCHEMBL28640226 0.71 ALDH1A1 (0.43) CYP3A4ALDH1A1MAPTRAB9APOLB
SCHEMBL31019228 0.71 ALDH1A1 (0.43) CYP3A4ALDH1A1MAPTRAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296972-B1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS AVENTIS PHARMA INC (US) 2009-12-23 EP disclosed
US-6977263-B2 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-12-20 US disclosed
US-20050228018-A1 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 US disclosed
US-20030187020-A1 Chemical compounds AVENTISUB LLC 2003-10-02 US disclosed
EP-1296972-A1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2003-04-02 EP disclosed
WO-2001090101-A1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228018-A1 Chemical compounds CMA1, TPSB2, TPSG1 GRM2 2266/4885CYP3A4 1205/4885MTNR1A 146/4885
US-20030187020-A1 Chemical compounds CMA1, TPSB2, TPSG1 GRM2 2266/4885CYP3A4 1205/4885MTNR1A 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.